Pediatr Infect Dis J. 2016;35(1):81-93. MenACWY-CRM was supplied in 2 vials: 1 vial of lyophilized powder containing 10 μg of MenA oligosaccharide conjugated to CRM 197 and a second liquid ...

The vaccine used in the RV144 trial is a combination of two vaccines given in a 'prime–boost' strategy: ALVAC-HIV from Sanofi Pasteur (Swiftwater, PA, USA) and AIDSVAX from VaxGene (San ...

Accessed September 2024. 9 Sanofi Pasteur Inc. Data on File. 10 Fluzone High-Dose [Prescribing Information]. Swiftwater, PA. 11 DiazGranados, Carlos A et. al. Efficacy of High-Dose versus Standard ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

PARIS (AP) — PARIS (AP) — Sanofi (SNY) on Friday reported third-quarter earnings of $3.09 billion. The company said it had net income of $1.23 per share. Earnings, adjusted for non-recurring costs, ...

The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...